IMPORTANT SAFETY INFORMATION:
Corzall™ Liquid (carbetapentane citrate and pseudoephedrine hydrochloride) 20 mg/30 mg per 5 mL is indicated for the symptomatic relief of the cough, coryza and nasal congestion associated with the common cold, sinusitis, allergic rhinitis and other upper respiratory tract conditions. Appropriate therapy should be provided for the primary disease. There are studies which demonstrate that carbetapentane has antitussive activity which may suppress or modify cough. Before prescribing medication to suppress or modify cough, identify and provide therapy for the underlying cause of the cough and take caution that modification of cough does not increase the risk of clinical or physiologic complications. Carbetapentane citrate should not be used in patients receiving MAO inhibitors, including 14 days after stopping the MAOI drug. The use of carbetapentane citrate may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression. Adverse effects associated with carbetapentane citrate are rare, but nausea and/or other gastrointestinal disturbances sometimes occur. Sympathomimetic amines are contraindicated in patients with severe hypertension, severe coronary heart disease and patients on monoamine oxidase (MAO) inhibitor therapy or for two weeks after stopping the MAOI drug. Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa, and mecamylamine. Effects of sympathomimetics are increased with MAO inhibitors and beta-adrenergic blockers. Sympathomimetics may cause mild central nervous system stimulation. Sympathomimetic drugs have also been associated with certain untoward reactions including fear, anxiety, tenseness, restlessness, tremor, weakness, pallor, respiratory difficulty, dysuria, insomnia, hallucinations, convulsions, CNS depression, CNS stimulation, nervousness, increased heart rate or blood pressure, arrhythmias, dizziness and cardiovascular collapse with hypotension.
For full prescribing information, please click here.

If you do not have Adobe® Acrobat® Reader for viewing the pdfs shown above, you may download it free of charge by clicking here.